Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria.

By P. Hillmen, C. Hall, J. Marsh, M. Elebute, M. Bombara, Beth E. Petro, M. Cullen, S. Richards, S. Rollins, C. Mojcik and 1 more. New England Journal of Medicine, 2004

619 citations recorded by the source corpus.

Subfields: Hematology, Immunology

View Paper: https://www.semanticscholar.org/paper/7a7e20622752bdf7c0912640e47834fd009b6419

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. S. Rollins
2. C. Mojcik
3. M. Gladwin
4. L. Bell

Citations in the corpus

• The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. (2005, background): “among PNH patients due to ongoing chronic intravascular hemolysis.(10,118,119) Lactate dehydrogenase is accepted as an”
• Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria (2007, background): “The first eculizumab PNH study (beginning in May 2002) evaluated terminal complement inhibition in a 3-month open-label phase 2 pilot study in 11 participants with hemolytic PNH at two sites in the United Kingdo”